The Wyss Diagnostics Accelerator Industrial Participant Program (Wyss DxA IPP) serves as a collaboration hub between healthcare testing companies, and the scientific and clinical community within the Wyss Institute, as well as our affiliated institutions and the broader Harvard ecosystem.
Partners build relationships and explore pre-competitive collaboration opportunities, connect with thought leaders and subject matter experts, identify key opportunities and challenges within the industry, and align on a vision to transform the future of diagnostic and healthcare testing, all driven by the passion to solve unmet diagnostic needs.
The Industrial Participant Program (IPP) is the industry-facing component of the Wyss Diagnostics Accelerator. Learn more about our current program participants below.
BioDot specializes in low volume fluid dispensing systems (picoliters to microliters) for product development and manufacturing in the diagnostic and life sciences industries. Every Drop Has A Story.
Contact: Debbie Bowers, Senior VP of Commercial Development, email@example.com
Innovative diagnostics for a better tomorrow. Ethos Laboratories strives to improve the lives of patients suffering from chronic disease through advanced diagnostic development and cutting edge research.
Contact: Joshua Gunn, Chief Scientific Officer, firstname.lastname@example.org
Folia Health is the platform for capturing actionable patient insights to better understand the burden of disease, patient journey, and impact of therapy across complex and rare conditions.
Contact: Nell Meosky Luo, CEO, email@example.com
Kephera Diagnostics is developing new, affordable point-of-care diagnostic tests for emerging infectious diseases on its mobile platform.
Contact: Andrew Levin, President and Scientific Director, firstname.lastname@example.org
Lifespin – understanding by data. LifeSpin is a health data insights company created to map the human health condition.
Contact: Ali Tinazli, CEO, email@example.com
Transforming community-based healthcare through innovative next generation diagnostic solutions.
Contact: Josh Pulido, Director of Global Product Marketing, firstname.lastname@example.org
Nemdx offers new tools, based on proprietary non-enzymatic molecular assays, for monitoring actively expressed genomic sequences, including ways to detect mutations, protein/nucleic acid interactions and protein splicing in the areas of neurodegenerative diseases and oncology.
Contact: Vito Levi D’Ancona, Founder, email@example.com
Utah Nano is an end-to-end manufacturer of micro- and nano-fabricated devices including microfluidics, lab-on-chip, organ-on-chip, wearables, diagnostics, and metamaterials.
Contact: Lexington Blood, C0-Founder, firstname.lastname@example.org
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals.
Contact: Stephane Shu Kin So, Director of Research Alliances and External Innovation, email@example.com
Trey Toombs is the Head of Operations and Outreach for the Wyss DxA Industrial Participant Program, applying his program management experience to help develop, launch and operationalize this new endeavor and facilitate collaborations that will accelerate the advancement of diagnostics. Trey also serves as a senior program manager for the Brigham Research Institute, where he works closely with faculty and institutional leaders to create and execute initiatives to foster new interdisciplinary and interdepartmental research and raise the visibility of the broader research enterprise. Previously, Trey was a research fellow at Massachusetts General Hospital, received his Ph.D. in biochemistry and molecular biology from Colorado State University and his B.S. from Virginia Tech. Contact: firstname.lastname@example.org
Bob Cunningham is responsible for engaging members of the business and philanthropic communities in the Institute’s mission of improving healthcare and the environment by accelerating the movement of breakthrough technologies from the laboratory to the market. To harness the power of the Institute’s renowned faculty and network of collaborating institutions to solve global challenges requires a community of dedicated supporters, like founding donor Hansjörg Wyss, who seek not only to enable the fundamental research needed to develop innovative solutions, but also see the results rapidly deployed for the public good through the Institute’s successful model of technology translation and product commercialization. Bob supervises the Strategic Engagement team to manage the Institute’s relationships with companies, foundations, and family offices to identify areas of mutual interest, and mobilize the resources to effect real-world change. Contact: email@example.com
Alex Li works closely with the Institute’s technical teams to strategize and translate technologies into market opportunities for commercialization. Prior to joining the Institute, Alex worked in seed venture capital where he managed and supported healthcare startups to reach successful exits through acquisition, licensing, and further financing rounds. Alex has also worked in agricultural biotechnology research to promote sustainability. He holds an M.B.A., Master of Business and Science (M.B.S.) in Genomics, and a B.S. in Biotechnology from Rutgers University, New Brunswick. Contact: firstname.lastname@example.org
Members of the Wyss DxA IPP Advisory Team bring their broad experiences and diverse backgrounds to help guide and grow the program to benefit its participants.
Sophie Allauzen is a Diagnostic expert with 20 years of experience in R&D, business development, and portfolio management in various industries/organizations managing full lifecycle (R&D, planning, commercialization, and registration) of novel diagnostic tests/systems globally. Her experience includes the Bill and Melinda Gates Foundation where she oversaw the malaria, neglected diseases and emerging disease diagnostic programs, Novartis Diagnostics as Head of Blood Testing running the NAT/Immunohematology product portfolio and Bio-Rad managing the R&D department for the development of bead multiarray immunoassays. Prior moving to the U.S., Sophie worked at Sanofi Diagnostics Pasteur in France, in R&D working on the development of various tests for infectious diseases.
Sharon Knight is healthcare startup executive, board member and investor with deep experience in finance, planning and operations. After leading diverse functions and multinational teams at companies such as KFC, Gap, and Electronic Arts, she entered the startup world, joining One Medical Group, an innovative primary care provider, in 2012 as President, overseeing its growth from 4 offices in San Francisco to 15 offices. Most recently, she was President and COO of Hawthorne Effect, a startup that is transforming how clinical trials are conducted. She is also the founder of Avik Ventures through which Sharon has made 14 investments and advised more than 30 companies.
Michael J. Natan, Ph.D. has over 25 years of entrepreneurial activity in the life science space. Michael is currently CEO of Spear Bio Inc., a startup focused on ultrasensitive protein diagnostics. During 2020, he was an entrepreneur-in-residence at Harvard, and a Principal at 3PoundFlax, LLC, helping seed-stage life science companies with strategy, IP, operations, and financing. He was previously President, CEO and a Director of Ultivue Inc., the leader in whole-slide tissue multiplexing technology. Prior to joining Ultivue, he was an Executive Director, New Business Development for Cabot Corporation. In 2010, Cabot acquired Oxonica Materials Inc., for which Michael served as CEO. Prior to Oxonica, Michael was a co-founder and CEO of Nanoplex Technologies Inc. (acquired by Oxonica), and served as CTO and then as VP, Business Development for SurroMed, the first biomarker discovery company. Dr. Natan started his professional career as an Assistant Professor, Associate Professor with tenure, and Full Professor of Chemistry at Penn State University from 1991-1999. His education comprised a degree in Chemistry with Honors from Yale University (1981), a Ph.D. in Chemistry from MIT (1986), and postdoctoral research at Northwestern University (1987-1991).
Jim Niemi has over 25 years of experience in medical device research, development, and commercialization. His prior interests and experience include neuromuscular stimulation and control, stochastic resonance for human neuromotor applications, advanced medical imaging, implantable smart sensors and materials, as well as bioreactor and automation design. Jim is currently the Lead Staff Engineer for the Living Cellular Devices focus area of the Wyss Institute focusing on applications of synthetic biology, in conjunction with traditional devices, for primarily diagnostic applications. Jim received his B.S. in Biomedical Engineering from Boston University and his M.S. in BioEngineering from Brown University. Contact: email@example.com
Mac Strafford is a healthcare professional with a background in management consulting. She currently oversees population health projects at Optum and previously served as a consultant at Bain & Company in the private equity practice. Throughout 2020, Mac also led Testing & Therapeutic efforts at a COVID-19 relief nonprofit called Stop the Spread. In this role, Mac supported over 100 diagnostic companies by connecting them with resources to accelerate their development timeline and enable greater scale.